BriaCell TherapeuticsBCTX 
$0.62-5.23%24h
-5.23%24h
Global rank30979
Market cap$9.62M
Change 7d-9.41%
YTD Performance-89.56%
SP500 benchmarkUnderperform
P/E-0.47
P/S0
Revenue$0
Earnings-$20.30M
Dividend yield-
BriaCell Therapeutics (BCTX) Stock Overview
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company also develops Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BCTX Stock Information
Symbol
BCTXAddress
Bellevue CentreWest Vancouver, BC V7T 2X1Canada
Founded
-Trading hours
-Website
https://briacell.comCountry
🇨🇦 CanadaPhone Number
604 921 1810BriaCell Therapeutics (BCTX) Price Chart
-
Value:-
BriaCell Therapeutics Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.616 | N/A |
| Market Cap | $9.62M | N/A |
| Shares Outstanding | 15.62M | 0.81% |
| Employees | 16.00 | N/A |
| Shareholder Equity | -5.05M | -136.57% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.47 | N/A |
| P/B Ratio | -1.90 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 4.0192 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$20.30M | N/A |
| EPS | -1.30 | N/A |
| Earnings Yield | -2.11 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $36.33M | N/A |
| Cash on Hand | $28.42M | N/A |
| Debt to Equity | -8.1915 | -362.37% |
| Current Ratio | $14.96 | -66.76% |
